（文章来源：证券日报） 证券日报网1月6日讯 ，中力股份在接受调研者提问时表示，综合国内外市场需求趋势、公司产品与解 决方案的客户接纳度，以及自身产能与交付能力的提升，公司预计数智物流业务在2026年有望实现规模 跨越，收入规模较2025年实现一倍左右的增长是可预期的目标。关于何时迎来"爆发性增长"，这是一个 更具战略性的问题。公司认为爆发性增长并非一个简单的时点，而是一个由需求和接纳共同作用的过 程：从市场需求上看，全球供应链重构到国内产业升级，智能化、柔性化物流解决方案的需求正在从可 选变为必选项。公司观察到无论是制造业的产能迭代，还是流通行业的效率革命，都为数智物流提供了 广阔的应用场景，整体需求总量持续攀升；从行业接纳度上看，在已实施的行业中，客户的接纳度也逐 渐规模化认同。同时得益于物流仓储行业案例提供的可参考性，数智物流业务正有序地向食品纺织、酒 水酿造、生物医药多个关键产业领域渗透，验证了解决方案的适配性与可复制性，市场的正向反馈增强 了公司的信心。因此虽然无法判断爆发性增长何时到来，但公司会积极配置战略资源，持续转化技术优 势，将行业解决方案不断横向拓展、纵向优化，在规模提速的起点上抓住机遇， ...

证券日报网讯 12月29日，云鼎科技（000409）在互动平台回答投资者提问时表示，公司目前专注于为 煤炭、化工、电力、新能源等能源企业提供信息化、智能化、数字化转型的综合解决方案与服务，主营 业务不涉及航天领域。 ...

格隆汇12月29日丨云鼎科技(000409.SZ)在互动平台表示，公司目前专注于为煤炭、化工、电力、新能 源等能源企业提供信息化、智能化、数字化转型的综合解决方案与服务，主营业务不涉及航天领域。 ...

Group 1 - The company, Yunding Technology (000409.SZ), is currently focused on providing comprehensive solutions and services for the energy sector, specifically coal, chemicals, electricity, and new energy, and does not have business involvement in the aerospace field [2] - In response to an investor inquiry on the interactive platform, the company clarified its business focus and confirmed that it does not engage in aerospace activities [2] - The company's main business revolves around information technology, intelligence, and digital transformation for energy enterprises [2]

格隆汇12月29日丨云鼎科技(000409.SZ)在投资者互动平台表示，公司深耕信息技术与能源行业融合的 细分领域，专注于为煤炭、化工、电力、新能源等能源企业提供信息化、智能化、数字化转型的综合解 决方案与服务。公司子公司北斗天地在北斗卫星通信和导航方面相关业务量较小，对公司业绩不构成重 大影响。公司始终密切关注国家战略导向与市场前沿动态，后续将继续夯实主业基础，同时以开放、前 瞻的视角，审时度势，动态优化产业布局，积极把握可能孕育的长期发展机遇，力求为投资者创造持 续、稳定的回报。 ...

格隆汇12月29日丨云鼎科技(000409.SZ)在投资者互动平台表示，公司深耕信息技术与能源行业融合的 细分领域，专注于为煤炭、化工、电力、新能源等能源企业提供信息化、智能化、数字化转型的综合解 决方案与服务。公司子公司北斗天地在北斗卫星通信和导航方面相关业务量较小，对公司业绩不构成重 大影响。公司始终密切关注国家战略导向与市场前沿动态，后续将继续夯实主业基础，同时以开放、前 瞻的视角，审时度势，动态优化产业布局，积极把握可能孕育的长期发展机遇，力求为投资者创造持 续、稳定的回报。 ...

（编辑 楚丽君） 证券日报网讯 12月17日，云鼎科技在互动平台回答投资者提问时表示，公司深耕信息技术与能源行业 融合的细分领域，结合能源行业智能化的发展需求及自身优势业务特点，深度融合5G、人工智能、大 数据、云计算、物联网等技术，专注于为煤炭、化工、电力、新能源等能源企业提供信息化、智能化、 数字化转型的综合解决方案与服务。公司具体经营业绩情况敬请关注公司发布的定期报告和临时公告。 ...

Core Viewpoint - The company has successfully developed an automated, intelligent, and integrated desktop synthesis system for antibody-drug conjugates (ADC) and nucleotide monomers in collaboration with East China Normal University, which enhances R&D efficiency and service quality [1] Group 1 - The full subsidiary of the company, Shanghai Ruizhi Pharmaceutical Research Group Co., Ltd., has partnered with East China Normal University to develop the new synthesis system [1] - The new system allows for seamless transition from laboratory research to industrial production, indicating a significant advancement in the production process [1] - The implementation of this system is expected to significantly shorten the R&D cycle and improve overall research efficiency [1]

Core Viewpoint - The collaboration between Shanghai Ruizhi Pharmaceutical Research Group and East China Normal University aims to advance drug discovery and delivery systems through the establishment of a cutting-edge technology joint laboratory, focusing on antibody-drug conjugates (ADC) and nucleotide monomer synthesis systems [1] Group 1: Collaboration and Research Focus - The partnership is based on a strategic cooperation framework agreement, emphasizing joint research in drug discovery, biochips, drug delivery systems, and drug conjugates [1] - The newly developed automated, intelligent, and integrated desktop synthesis systems for ADC and nucleotide monomers enable seamless transition from laboratory research to industrial production [1] Group 2: Technological Advancements - The ADC microfluidic manufacturing system integrates ultra-fast laser microfluidic chips with intelligent process control, transitioning antibody drug conjugation from intermittent operations to platform-based manufacturing [1] - The nucleotide monomer microfluidic synthesis system utilizes a catalyst-free and base-free "intelligent microfluidic" approach for the continuous, stable, and green synthesis of phosphoramidite monomers, establishing new standards for the supply of nucleic acid drug materials [1] Group 3: Impact on R&D Efficiency - The implementation of these automated and intelligent synthesis systems is expected to significantly shorten research and development cycles and enhance R&D efficiency, ultimately providing better services to clients [1]

Core Viewpoint - The company has established a cutting-edge technology joint laboratory with East China Normal University to enhance research in drug discovery, biochips, drug delivery systems, and drug conjugates (XDC) [1] Group 1: Collaboration and Research Development - The collaboration is based on a strategic cooperation framework agreement, aiming to advance research in various pharmaceutical fields [1] - The joint efforts have led to the successful development of an automated, intelligent, and integrated desktop synthesis system for antibody-drug conjugates (ADC) and nucleotide monomers [1] Group 2: Technological Advancements - The ADC microfluidic manufacturing system integrates ultra-fast laser microfluidic chips with intelligent process control, transitioning antibody drug conjugation from "batch operation" to "platform-based intelligent manufacturing" [1] - The nucleotide monomer microfluidic synthesis system utilizes a "smart microfluidic" approach without catalysts or alkali participation, enabling continuous, stable, and green synthesis of phosphoramidite monomers [1] Group 3: Impact on R&D Efficiency - The implementation of these automated and intelligent synthesis systems is expected to significantly shorten research and development cycles and enhance R&D efficiency [1] - This advancement will allow the company to provide higher quality services to its clients [1]